### Coronaropathies et Anticoagulants

### Journée d'Actualités Thérapeutiques ACCA Nice 12 septembre 2020

Nicolas MENEVEAU CHU Jean Minjoz Besançon

### Disclosures

### Speaker: Nicolas Meneveau

✓ I have the following potential conflicts of interest to declare:


### **Consultant:**

Abbott, Alliance BMS/Pfizer, Bayer, Edwards Lifesciences, Sanofi Regeneron, Terumo

### Honoraria:


AstraZeneca

# Clinical challenge in patients with atrial fibrillation undergoing PCI



Schömig et al. NEJM 1996. Connolly et al Lancet 2006. Capodanno D, Angiolillo DJ. JACC: Cardiovascular Interventions 2017.

## Bleeding and triple therapy after ACS/PCI in patients with atrial fibrillation




Graph shows crude incidence of fatal and nonfatal bleeding according to antithrombotic regimen in time following inclusion. Triple therapy includes aspirin, clopidogrel, and VKAs; VKA + single APT includes VKA + aspirin or clopidogrel; dual APT includes aspirin and clopidogrel; VKA monotherapy includes only VKA; single APT includes aspirin or clopidogrel. APT, antiplatelet therapy; MI, myocardial infarction; VKA, vitamin K antagonist.

Lamberts, et al. Circulation 2012;126:1185-93.

# For patients undergoing PCI, major bleeding is associated with increased in-hospital mortality

Data from 3,386,688 procedures in the CathPCI Registry in the US 2004-2011



CI, confidence interval; PCI, percutaneous coronary intervention.

Chatriwalla AK, et al. JAMA 2013;309:1022-9.

# Combinations of antiplatelet and antithrombotic agents in patients with AF and stent placement

#### **2.8 million different combinations!**

ASA dose	None	Low	High				2	1+8 = 9	
ASA duration, months	1	3	6	12			4	ASA	
Thienopyridine	None	Clop	Ticlo	Pras	Ticag		4	1+16 = 17	
Thienopyridine duration, months	1	3	6	12			4	Thieno	
AC	None	Warf	Dabi	Riva	Аріх	Edox	5	1+10 = 11	
AC INR/dose		Low	High				2	ACs	

Permutations of single, dual or triple therapy as early initial therapy (0, 1, 3, 6 months) following ACS: 9 x 17 x 11 = 1,683 Permutations of single or dual therapy late after early therapy (0, 1, 3, 6, 12 months) following ACS: 1,683


Total permutations throughout one year: 2.8 million

AC, anticoagulant; ASA, acetylsalicylic acid; INR, international normalised ratio.

Gibson CM. JACC 2017;69:172-5.

### Triple therapy with aspirin, prasugrel and vitamin K antagonists after DES implantation

377 consecutive patients (2009–2011) with an indication for OAC treated with a 6-month regimen of aspirin and either prasugrel (N=21) or clopidogrel (N=356)




MACCE, major adverse cardiovascular and cerebrovascular ischaemic event(s).

#### Sarafoff N, et al. J Am Coll Cardiol 2013;61:2060–6.

### **WOEST** : Trial results

**573 patients** on OAC undergoing stent (DES/BMS) implantation received oral anticoagulants<sup>\*</sup> + clopidogrel 75 mg qd<sup>\*\*</sup> and randomised 1:1 to also receive aspirin 80 mg OR aspirin placebo qd



\*INR as originally indicated; \*\*BMS: 1 month; DES and/or ACS:1 year.


BMS, bare-metal stent; DES, drug eluting stent implantation; qd; once daily; ST, stent thrombosis; TVR, target-vessel revascularisation.

#### Dewilde W, et al. Lancet 2013;381:1107–15.

### **ISAR-TRIPLE : Trial results**

Duration of triple therapy in 600 Pts requiring oral anticoagulation after DES implantation

#### 6-week vs 6-month triple therapy (1:1 randomisation)



# Safety and efficacy of dual vs. triple antithrombotic therapy in patients with AF following PCI

#### **PIONEER AF-PCI<sup>2</sup> RE-DUAL PCI<sup>3</sup>** Rivaroxaban 15 mg OD<sup>≠</sup> + P2Y<sub>12</sub> Warfarin + P2Y<sub>12</sub> inhibitor + ASA inhibitor for 12 months for 1 to 3 months N = 2124NVAF who N = 27251:1:1 had AF who had undergone Rivaroxaban 2.5 mg BID<sup>≠</sup> + R Dabigatran 110 mg BID<sup>+</sup> undergone PCI with DAPT for 1, 6, 12 months PCI stenting + P2Y<sub>12</sub> Dabigatran 150 mg BID VKA + DAPT for 1, 6, 12 months + P2Y<sub>12</sub> In PIONEER AF-PCl<sup>2</sup> $P2Y_{12}$ = clopidogrel, prasugrel, or ticagrelor In RE-DUAL<sup>3</sup> P2Y<sub>12</sub> = clopidogrel or ticagrelor

#### PIONEER AF-PCI<sup>2</sup> demonstrated significantly less bleeding in either rivaroxaban containing arm compared to VKA plus DAPT.

In patients where DAPT (ASA + P2Y<sub>12</sub>) was received for < 12 months SAPT (ASA) was given instead

- 1. Lopes RD et al. Am Heart J. 2018;200:17-23
- 2. Adapted from Gibson CM et al. N Engl J. Med. 2016;375:2423-2434
- 3. Adapted from Cannon CP et al. N Engl J. Med. 2017;377:1513-1524

4. Rivaroxaban US labeling package insert available at www.accessdata.fda.gov/scripts/cder/daf/ accessed April 2018


5. Rivaroxaban SmPC available at www.ema.europa.eu accessed April 2018

RE-DUAL PCI<sup>3</sup> demonstrated significantly less major or CRNM bleeding in each of the dabigatran strategies compared to the VKA strategy.

## Pioneer AF-PCI: Primary safety and secondary efficacy endpoints

#### Primary safety endpoint

#### Secondary efficacy endpoint



### PIONEER: Cumulative incidence of secondary outcomes

	Riva 15 mg + P2Y <sub>12</sub> inh (grp1) N = 694	Riva 2.5 mg + DAPT (grp 2) N = 704	Warfarin + DAPT (grp3) N = 695	Group 1 vs Group 3	Group 2 vs Group 3
	N (%)	N (%)	N (%)	<b>HR</b> (95% CI)	<b>HR</b> (95% CI)
CV death	15 (2.4)	14 (2.2)	11 (1.9)	1.29 (0.59–2.8)	1.19 (0.54–2.62)
Stroke	8 (1.3)	10 (1.5)	7 (1.2)	1.07 (0.39–2.96)	1.36 (0.52–3.58)
МІ	19 (3.0)	17 (2.7)	21 (3.5)	0.86 (0.46–1.59)	0.75 (0.40–1.42)
Stent thrombosis	5 (0.8)	6 (0.9)	4 (0.7)	1.20 (0.32–4.45)	1.44 (0.40–5.09)


Use of NOACs was not associated with increased cardiovascular outcomes compared with VKA

CV, cardiovascular; DAPT, dual antiplatelet therapy; MI, myocardial infarction.


Gibson et al. N Engl J Med 2016;375:2423–34.

### RE-DUAL PCI: Major or clinically relevant bleeding

2,725 patients with atrial fibrillation undergoing PCI



### **RE-DUAL PCI: Secondary efficacy endpoints**



#### Cannon C, et al. N Engl J Med 2017;377:1513–24.

### RE-DUAL : What about MACEs ? Incidence of selected secondary efficacy outcomes


		/ with dabigather therapy wit	atran (110 mg) vs h warfarin	Dual therapy with dabigatran (150 mg) vs triple therapy with warfarin				
	<b>110 mg dual</b> therapy N=981	therapy therapy (95% C		<b>150 mg dual</b> therapy N=763	<b>Triple</b> therapy N=764	<b>HR</b> (95% CI)		
	N (%)	N (%)		N (%)	N (%)			
Death	55 (5.6)	48 (4.9)	1.12 (0.76–1.65)	30 (3.9)	35 (4.6)	0.83 (0.51–1.34)		
Stroke	17 (1.7)	13 (1.3)	1.30 (0.63–2.67)	9 (1.2)	8 (1.0)	1.09 (0.42–2.83)		
МІ	44 (4.5)	29 (3.0)	1.51 (0.94–2.41)	26 (3.4)	22 (2.9)	1.16 (0.66–2.04)		
Definite stent thrombosis	15 (1.5)	8 (0.8)	1.86 (0.79–4.40)	7 (0.9)	7 (0.9)	0.99 (0.35–2.81)		

The absolute number of stent thrombosis was low

CV, cardiovascular; DAPT, dual antiplatelet therapy; MI, myocardial infarction.

Cannon C, et al. N Engl J Med 2017;377:1513–24.

# Safety and efficacy of dual vs. triple antithrombotic therapy in patients with AF following PCI





#### In RE-DUAL<sup>3</sup> P2Y<sub>12</sub> = clopidogrel or ticagrelor

These trials were not powered or designed to assess whether the bleeding reduction was due to the use of a NOAC or the removal of aspirin from the post-PCI oral antithrombotic strategy.<sup>1</sup>

In patients where DAPT (ASA +  $P2Y_{12}$ ) was received for < 12 months SAPT (ASA) was given instead


1. Lopes RD et al. Am Heart J. 2018;200:17-23

- 2. Adapted from Gibson CM et al. N Engl J. Med. 2016;375:2423-2434
- 3. Adapted from Cannon CP et al. N Engl J. Med. 2017;377:1513-1524

4. Rivaroxaban US labeling package insert available at www.accessdata.fda.gov/scripts/cder/daf/ accessed April 2018

5. Rivaroxaban SmPC available at www.ema.europa.eu accessed April 2018

### **AUGUSTUS : Study design**




BID, twice daily; INR, international normalised ratio.

### AUGUSTUS primary Outcome : Apixaban vs VKA

### **ISTH major or CRNM bleeding**

### **Death or hospitalization**




### AUGUSTUS secondary outcome : Composite of ischaemic events : Apixaban vs VKA

Endpoint	<b>Apixaban</b> (N=2306)	<b>VKA</b> (N=2308)	<b>HR</b> (95% CI)	
Death/Ischaemic events (%)	6.7	7.1	0.93 (0.75–1.16)	
Death (%)	3.3	3.2	1.03 (0.75–1.42)	
CV death (%)	2.5	2.3	1.05 (0.72–1.52)	
Stroke (%)	0.6	1.1	0.50 (0.26–0.97)	
Myocardial infarction (%)	3.1	3.5	0.89 (0.65–1.23)	
Definite or probable stent thrombosis (%)	0.6	0.8	0.77 (0.38–1.56)	
Urgent revascularisation (%)	1.7	1.9	0.90 (0.59–1.38)	
Hospitalisation (%)	22.5	26.3	0.83 (0.74–0.93)	

## AUGUSTUS primary Outcome : aspirin vs placebo

### **ISTH major or CRNM bleeding**

### **Death or hospitalization**




ARR, absolute risk reduction; CI, confidence interval; HR, hazard ratio; NNT, number needed to treat.

Lopes RD, et al. N Engl J Med 2019;doi:10.1056/NEJMoa1817083; Lopes RD. Final-AUGUSTUS-Main-Results-ACC19-PRESENTATION-17-March-2019.

### AUGUSTUS secondary outcome: Death or ischaemic events : aspirin vs aspirin placebo

Endpoint	<b>Aspirin</b> (N=2,307)	<b>Placebo</b> (N=2,307)	<b>HR</b> (95% CI)
<b>Death</b> , n (%)	<b>72</b> (3.1)	<b>79</b> (3.4)	<b>0.91</b> (0.66–1.26)
<b>CV death</b> , n (%)	<b>53</b> (2.3)	<b>58</b> (2.5)	<b>0.92</b> (0.63–1.33)
<b>Stroke</b> , n (%)	<b>20</b> (0.9)	<b>19</b> (0.8)	<b>1.06</b> (0.56–1.98)
Myocardial infarction, n (%)	<b>68</b> (2.9)	<b>84</b> (3.6)	<b>0.81</b> (0.59–1.12)
Definite or probable stent thrombosis, n (%)	<b>11</b> (0.5)	<b>21</b> (0.9)	<b>0.52</b> (0.25–1.08)
Urgent revascularisation, n (%)	<b>37</b> (1.6)	<b>47</b> (2.0)	<b>0.79</b> (0.51–1.21)
Hospitalisation, n (%)	<b>585</b> (25.4)	<b>540</b> (23.4)	<b>1.10</b> (0.98–1.24)

### AUGUSTUS : Stent Thrombosis Definite/Probable Stent Thrombosis



The number needed to treat (NNT) to avoid 1 stent thrombosis event for aspirin versus placebo at 6 months is 222 and the number need to harm (NNH) to cause 1 major bleeding event is 41.

Safety and efficacy of dual vs. triple antithrombotic therapy in patients with AF following PCI : ENTRUST-AFPCI

0


30

60

90

120

150



Days from randomization

180

210

240

Number of events:

Edoxaban: 128/751

270

HR (95% CI): 0.83 (0.65: 1.05) P-value (non-inferiority): 0.0010

300

360

330

P-value (superiority): 0.1154

VKA: 152/755


### Meta-analysis of pooled data from CRT : Bleeding : NOAC better than VKA


#### **NOAC-based regimens associated with significantly less** bleeding than VKA-based regimens

#### (B) NOACs versus VKA

#### **ISTH Major bleeding**

Study name		<u>Statis</u>	tics for ea	ach study		Odds ratio and 95% Cl
	Odds ratio	Lower limit	Upper limit	Z-Value	<i>P</i> -Value	
PIONEER AF-PC	0.521	0.348	0.780	-3.170	0.002	🔶
<b>RE-DUAL PCI</b>	0.551	0.408	0.746	-3.867	0.000	井
AUGUSTUS	0.644	0.472	0.878	-2.784	0.005	
POOLED	0.577	0.477	0.698	-5.652	0.000	
Г						0.1 0.2 0.5 1 2 5
	-42%	6				Favours NOACs Favours war






Fixed effects meta-analysis Q = 0.814, P = 0.666; I<sup>2</sup>: 0%

#### **CRNM** Bleeding

Study name		Statistics for each study						
	Odds ratio	Lower limit	Upper limit	Z-Value	<i>P</i> -Value			
PIONEER AF-PCI	0.671	0.525	0.858	-3.188	0.001			
<b>RE-DUAL PCI</b>	0.645	0.519	0.802	-3.945	0.000			
AUGUSTUS	0.698	0.571	0.854	-3.493	0.000			
POOLED	0.673	0.593	0.763	-6.136	0.000			
Г								






Odds ratio and 95% Cl

#### TIMI Minor bleeding

Study name		ach study			
	Odds ratio	Lower limit	Upper limit	Z-Value	<i>P</i> -Value
PIONEER AF-PCI	0.531	0.248	1.135	-1.633	0.102
RE-DUAL PCI	0.449	0.266	0.758	-2.999	0.003
AUGUSTUS	0.657	0.491	0.878	-2.841	0.004
POOLED	0.593	0.466	0.755	-4.253	0.000
	-31%	6			

#### Odds ratio and 95% CI




#### Potpara TS et al. Europace. 2020 Jan 1:22(1):33-46.

### Meta-analysis of pooled data from RCT : Bleeding : DAT better than TAT

### DAT-based regimens were associated with significantly less bleeding than TAT-based regimens

#### (A) DAT versus TAT




ISTH Major bleeding

Fixed effects meta-analysis Q = 1.093, P = 0.579; I<sup>2</sup>: 0%

#### ISTH CRNM bleeding

Study name		Statis	Statistics for each study				Odds ratio and 95% Cl				
	Odds ratio	Lower limit	Upper limit	Z-Value	P-Value						
PIONEER AF-P	CI 0.769	0.591	1001	-1.953	0.051		-==-				
RE-DUAL PCI	0.645	0.519	0.802	-3.945	0.000						
AUGUSTUS	0.506	0.410	0.623	-6.398	0.000						
POOLED	0.613	0.537	0.698	-7.346	0.000		•				
	_30%					0.1 0.2	0.5 1	2	5	10	
L L	-3570	<u></u>				Favou	irs DAT F	avour	rs TAT	Γ	

Random effects meta-analysis Q = 6.344, P = 0.042; I<sup>2</sup>: 68%



TIMI Major bleeding

#### TIMI Minor bleeding

Study name		Stat	tistics for e	ach study		Odds ratio and 95% Cl
	Odds ratio	Lower limit	r Upper limit	Z-Value	P-Value	
PIONEER AF-PC	0.703	0.296	1.669	-0.799	0.424	
RE-DUAL PCI	0.449	0.266	0.758	-2.999	0.003	
AUGUSTUS	0.549	0.408	0.739	-3.960	0.000	
POOLED	0.535	0.418	0.686	-4.947	0.000	
Г						0.1 0.2 0.5 1 2 5 10
	-47%					Favours DAT Favours TAT

Fixed effects meta-analysis Q = 0.842, P = 0.656; I<sup>2</sup>: 0%

#### Potpara TS et al. Europace. 2020 Jan 1;22(1):33-46.

Fixed effects meta-analysis Q = 2.326, P = 0.313; I<sup>2</sup>: 14%

### Meta-analysis of pooled data from RCT : Myocardial infarction & stent thrombosis

#### Higher rates of ST with DAT vs TAT

#### (A) DAT versus TAT

#### Myocardial infarction

Study name		Odds ratio and 95% CI					
	Odds ratio	Lower limit	Upper limit	Z-Value	P-Value		
PIONEER AF-PCI	1.008	0.577	1.762	0.028	0.977	_+	
RE-DUAL PCI	1.291	0.828	2.013	1.129	0.259		
AUGUSTUS	1.244	0.899	1.722	1.317	0.188		
POOLED	1.211	0.955	1.535	1.578	0.115		
						0 4 0 0 0 F 4 0 F	

0.1 0.2 0.5 1

Favours DAT Favours TAT

Fixed effects meta-analysis Q = 0.521, P = 0.771; I<sup>2</sup>: 0%

#### Stent thrombosis

Study name	tudy name Statistics for each study					Odd	dds ratio and 95% CI					
	Odds ratio	Lower limit	Upper limit	Z-Value	P-Value							
PIONEER AF-PCI	1.370	0.435	4.318	0.538	0.591		+	+	+	-		
RE-DUAL PCI	1.554	0.689	3.503	1.063	0.288		-	┿		-		
AUGUSTUS	1.923	0.925	4.001	1.750	0.080			+		-		
POOLED	1.672	1.022	2.733	2.048	0.041							
						0.1 0.2	0.5	1	2	5		

Favours DAT Favours TAT

5 10

#### Similar rates of MI & ST with NOAC vs VKA

Myocardial infarction

#### (B) NOAC versus VKA

#### Study name Statistics for each study Odds ratio and 95% Cl Odds Lower Upper limit. Z-Value P-Value PIONEER AF-PCI 0.848 -0.5900.555 0.491 1.465 RE-DUAL PCI 1,291 0.828 2.013 1,129 0.259 AUGUSTUS 1 241 -0.6540.513 0.898 0 649 POOLED 0.984 0.777 1.246 -0.1320.895



Favours NOACs Favours warfarin

Fixed effects meta-analysis Q = 2.033. P = 0.362; I<sup>2</sup>: 2%

#### Stent thrombosis

Study name		Statist	ics for ea	ach study			Odd	s ratio	ano	1 95%	CI
	Odds ratio	Lower limit	Upper limit	Z-Value	P-Value						
PIONEER AF-PCI	1.370	0.435	4.318	0.538	0.591			+	+	+	-1
RE-DUAL PCI	1.554	0.689	3.503	1.063	0.288			-	┿		
AUGUSTUS	0.776	0.385	1.564	-0.710	0.478			-+-		.	
POOLED	1.095	0.676	1.773	0.368	0.713				•		
						0.1	0.2	0.5	1	2	5

Favours NOACs Favours warfarin


Fixed effects meta-analysis Q = 1.787, P = 0.409; I<sup>2</sup>: 0%

#### Potpara TS et al. Europace. 2020 Jan 1;22(1):33-46.

10 5

Fixed effects meta-analysis Q = 0.287, P = 0.866; I<sup>2</sup>: 0%


### ESC 2018 Joint European consensus, endorsed by Asia Pacific Heart Rhythm Society



1. Periprocedural administration of aspirin and clopidogrel during PCI is recommended irrespective of the treatment strategy; as dual therapy, potent P2Y<sub>12</sub> inhibitors (ticagrelor) may be combined with dabigatran; 2. High atherothrombotic risk (for elective PCI, use SYNTAX score; for ACS, Grace score >140; stenting of the left main, proximal LAD, proximal bifurcation; recurrent MIs; stent thrombosis etc.) and low bleeding risk; 3. Bleeding risk can be estimated using the HAS-BLED score; correct modifiable bleeding risk factors.

ESC, European Society of Cardiology; NOAC, non-VKA oral anticoagulant; TTR = Time in Therapeutic Range.

### 2018 North American expert consensus document



SAPT, single antiplatelet therapy.

OAC: prefer a NOAC over VKA if no contraindications; SAPT: prefer a P2Y<sub>12</sub> inhibitor over aspirin.

Clopidogrel is the P2Y<sub>12</sub> inhibitor of choice; ticagrelor may be considered in patients at high ischaemic/thrombotic and low bleeding risks; avoid prasugrel. Consider SAPT in addition to OAC after >12 months only in select patients at high ischaemic/thrombotic and low bleeding risks.

## Patients with angina and/or dyspnoea and coronary artery disease - Event prevention (9)



Recommendations	Class	Level				
Antithrombotic therapy in post-PCI patients with AF or another indication for an OAC						
After <u>uncomplicated PCI, early cessation (≤1 week) of aspirin</u> and continuation of dual therapy with an OAC and clopidogrel should be considered if the risk of stent thrombosis <sup>a</sup> is low, or if concerns about bleeding risk prevail over concerns about the risk of stent thrombosis, <sup>a</sup> irrespective of the type of stent used.	lla	В				
Triple therapy with aspirin, clopidogrel, and an OAC for $\geq 1$ month should be considered when the risk of stent thrombosis <sup>a</sup> outweighs the bleeding risk, with the total duration ( $\leq 6$ months) decided according to assessment of these risks and clearly specified at hospital discharge.	lla	С				
In patients with an indication for a VKA in combination with aspirin and/or clopidogrel, the dose intensity of the VKA should be carefully regulated with a target international normalized ratio in the range of 2.0-2.5 and with time in therapeutic range >70%.	lla	В				
<sup>a</sup> Risk of stent thrombosis encompasses (i) the risk of thrombosis occurring and (ii) the risk of death should stent thrombosis occur, both of which relate to						

<sup>a</sup> Risk of stent thrombosis encompasses (i) the risk of thrombosis occurring and (ii) the risk of death should stent thrombosis occur, both of which relate to anatomical, procedural, and clinical characteristics. Risk factors for CCS patients include stenting of left main stem, proximal LAD, or last remaining patent artery; suboptimal stent deployment; stent length >60 mm; diabetes mellitus; CKD; bifurcation with two stents implanted; treatment of chronic total occlusion; and previous stent thrombosis on adequate antithrombotic therapy.

## Patients with angina and/or dyspnoea and coronary artery disease - Event prevention (10)



Recommendations	Class	Level
Antithrombotic therapy in post-PCI patients with AF or another indication for an OAC		
Dual therapy with an OAC and either ticagrelor or prasugrel may be considered as an alternative to triple therapy with an OAC, aspirin, and clopidogrel in patients with a moderate or high risk of stent thrombosis, <sup>a</sup> irrespective of the type of stent used.	llb	С
The use of ticagrelor or prasugrel is not recommended as part of triple antithrombotic therapy with aspirin and an OAC.	ш	С
<sup>a</sup> Risk of stent thrombosis encompasses (i) the risk of thrombosis occurring and (ii) the risk of death should stent thrombosis occur, both of wh anatomical, procedural, and clinical characteristics. Risk factors for CCS patients include stenting of left main stem, proximal LAD, or last rema suboptimal stent deployment; stent length >60 mm; diabetes mellitus; CKD; bifurcation with two stents implanted; treatment of chronic total	ining patent a	• •

©ESC

stent thrombosis on adequate antithrombotic therapy.

### Conclusion : AF and coronary revascularization

- Which anticoagulant treatment: In most patients, NOACs should be preferred over VKA unless contraindicated
- Which P2Y<sub>12</sub> inhibitor : Clopidogrel is the first-line choice; ticagrelor may be an alternative in patients at high ischemic/thrombotic and low bleeding risk; prasugrel should be avoided.
- When and for Whom: Dual-therapy (OAC plus P2Y12 inhibitor) immediately or early after hospital discharge should be considered for most patients. Triple-therapy (extended use of aspirin beyond hospital discharge) should be considered only for patients at high ischemic/thrombotic\* and low bleeding risks. Duration should be limited (e.g. 1 month)

\*High atherothrombotic risk as assessed by SYNTAX score (PCI), Grace score > 140 (ACS), stenting of left main or proximal LAD; proximal bifurcation, recurrent ACS, stent thrombosis.... \*Bleeding risk as assessed by HAS-BLED score, BARC Consensus